A lawyer for the employers predicts that discovery will show that collusion between drugmakers and PBMs had a significant impact on his clients' costs.

She promised to work with businesses and fight to protect the current Affordable Care Act premium subsidy levels.

Walz supports a state public option effort but never backed the House Medicare for All Act bills.

A settlement between the drugmaker and insulin patients that would have capped patients' out-of-pocket insulin costs at $35 for 4 years has fallen apart, after an "unfavorable ruling" from the judge overseeing the case.